When TNF inhibitors fail in RA—weighing up the options

被引：0
|
作者：
Lucia Silva-Fernandez
Kimme Hyrich
机构：
[1] Arthritis Research UK Centre for Epidemiology,
[2] Centre for Musculoskeletal Research,undefined
[3] Institute of Inflammation and Repair,undefined
[4] the University of Manchester,undefined
[5] Manchester Academic Health Science Centre,undefined
来源：
Nature Reviews Rheumatology | 2014年 / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
What is the best rheumatoid arthritis therapy after failure of a first anti-TNF drug? No consensus has been reached on whether to switch to rituximab or an alternative TNF inhibitor. New observational studies suggest that either course can be effective. But are more data needed?
引用
收藏
页码：262 / 264
页数：2
相关论文
共 50 条
  • [31] Hodgkin Lymphoma: What to Do When Checkpoint Inhibitors Fail
    Armand, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S19 - S19
  • [32] Adverse effects of TNF inhibitors in SpA: Are they different from RA?
    Sampaio-Barros, Percival D.
    van der Horst-Bruinsma, Irene E.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2014, 28 (05): : 747 - 763
  • [33] RHEUMATOID ARTHRITIS TNF inhibitors and cardiovascular risk management in RA
    Pope, Janet E.
    NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (06) : 317 - U17
  • [34] RoActemra((R)) (Tocilizumab) - Rapid and persistent Remission in RA when DMARDs fail
    不详
    JOURNAL FUR MINERALSTOFFWECHSEL, 2009, 16 (03): : 162 - 162
  • [35] Set Up to Fail: Explaining When Women-Led Businesses Are More Likely to Fail
    Yang, Tiantian
    Triana, Maria del Carmen
    JOURNAL OF MANAGEMENT, 2019, 45 (03) : 926 - 954
  • [36] Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?
    Saleem, Benazir
    Keen, Helen
    Goeb, Vincent
    Parmar, Rekha
    Nizam, Sharmin
    Hensor, Elizabeth M. A.
    Churchman, Sarah M.
    Quinn, Mark
    Wakefield, Richard
    Conaghan, Philip G.
    Ponchel, Frederique
    Emery, Paul
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (09) : 1636 - 1642
  • [37] IL-1ra plus TNF-SR fail to improve sepsis survival
    Bolgos, G
    Call, D
    Ebong, S
    Newcomb, D
    Remick, D
    FASEB JOURNAL, 1998, 12 (05): : A808 - A808
  • [38] USE OF TNF INHIBITORS IS ASSOCIATED WITH A REDUCED RISK OF DIABETES IN RA PATIENTS
    Lillegraven, S.
    Greenberg, J. D.
    Reed, G. W.
    Saunders, K.
    Curtis, J. R.
    Harrold, L.
    Hochberg, M. C.
    Pappas, D.
    Kremer, J. M.
    Solomon, D. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 106 - 107
  • [39] Use Of TNF Inhibitors Is Associated With a Reduced Risk Of Diabetes In RA Patients
    Lillegraven, Siri
    Greenberg, Jeffrey D.
    Reed, George W.
    Saunders, Katherine C.
    Curtis, Jeffrey R.
    Harrold, Leslie R.
    Hochberg, Marc C.
    Pappas, Dimitrios A.
    Kremer, Joel M.
    Solomon, Daniel H.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S443 - S444
  • [40] Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma
    Spain, Lavinia
    Larkin, James
    IMMUNOTHERAPY, 2016, 8 (06) : 677 - 679
12345